대장암 진단 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Colorectal Cancer Diagnostics Market was valued at USD 15.2 billion in 2024 and is projected to grow at a CAGR of 8.9% from 2025 to 2034. Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide, affecting millions of individuals each year. With CRC incidence rates rising, particularly among younger adults, the need for accurate, efficient, and early diagnostic solutions has never been more critical. Early detection significantly improves survival rates, making advanced diagnostic technologies essential for timely intervention.

The market for colorectal cancer diagnostics is expanding rapidly due to continuous advancements in imaging technologies, liquid biopsy, and AI-powered diagnostic tools. Increasing awareness campaigns and government-backed CRC screening programs across key regions are further driving demand for reliable and accessible diagnostic methods. Leading market players are actively investing in the development of high-precision, non-invasive testing solutions that cater to both clinical settings and at-home screening. The growing adoption of stool-based DNA tests, blood biomarker screenings, and AI-driven imaging solutions is revolutionizing CRC diagnostics, ensuring patients receive early and accurate assessments.

The colorectal cancer diagnostics market is segmented by test type, including blood tests, stool tests, imaging tests, biopsies, and other diagnostic methods. Imaging tests dominated the market with a 49.6% share in 2024, driven by the rising demand for early cancer detection and accurate disease assessment. Advanced imaging technologies, particularly PET-CT scans and AI-assisted radiology, play a crucial role in detecting colorectal malignancies at an early stage. These high-precision tools enhance diagnostic accuracy, facilitating personalized treatment approaches. Stool-based tests, including fecal occult blood tests and CRC DNA screenings, are also gaining traction due to their non-invasive nature, making them a preferred choice for large-scale screening programs.

The market is further categorized based on end use, with hospitals, diagnostic imaging centers, and cancer research institutions emerging as key segments. Hospitals accounted for 40.8% of the market share in 2024, primarily due to their advanced oncology and gastroenterology departments. The availability of comprehensive diagnostic facilities, skilled healthcare professionals, and integrated CRC screening programs has positioned hospitals as the leading diagnostic setting. Governments worldwide continue to implement nationwide colorectal cancer screening initiatives, further fueling hospital-based diagnostic testing.

The U.S. colorectal cancer diagnostics market generated USD 5 billion in 2024, reflecting a strong demand for early detection solutions. The rising incidence of CRC among younger populations, combined with growing awareness of the importance of early screening, is driving market expansion. The increased availability of at-home diagnostic solutions, such as blood biomarkers and stool-based tests, has made CRC screening more accessible, allowing individuals to take proactive steps toward early detection. As technological advancements continue to shape the diagnostic landscape, demand for highly accurate, non-invasive, and AI-powered colorectal cancer screening solutions is expected to surge, solidifying the U.S. as a key growth hub for the global market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence and prevalence of colorectal cancer
    • 3.2.1.2 Government initiatives and policies associated with cancer screening tests
    • 3.2.1.3 Technological advancements in field of cancer diagnostics
    • 3.2.1.4 Growing awareness regarding early diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of diagnostic tests and procedures
    • 3.2.2.2 Lack of reimbursement policies for diagnostic tests
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Gap analysis
• 3.7 Patent analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Blood tests
• 5.3 Stool tests
  • 5.3.1 Fecal occult blood test (FOBT)
  • 5.3.2 Fecal biomarker test
  • 5.3.3 CRC DNA screening test
• 5.4 Imaging tests
  • 5.4.1 CT
  • 5.4.2 Ultrasound
  • 5.4.3 MRI
  • 5.4.4 PET
  • 5.4.5 Colonoscopy
  • 5.4.6 Other imaging tests
• 5.5 Biopsy
• 5.6 Other test types

Chapter 6 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hospitals
• 6.3 Diagnostic imaging centers
• 6.4 Cancer research centers
• 6.5 Other end use

Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 Becton, Dickinson and Company
• 8.3 Danaher Corporation
• 8.4 Exact Sciences Corporation
• 8.5 F-Hoffmann-La Roche
• 8.6 Fujirebio
• 8.7 GE Healthcare
• 8.8 Geneoscopy
• 8.9 Guardant Health
• 8.10 Hologic
• 8.11 NeoGenomics Laboratories
• 8.12 Qiagen
• 8.13 Siemens Healthineers
• 8.14 Sysmex Corporation
• 8.15 Thermo Fischer Scientific